| Literature DB >> 27136520 |
Weng-Keong Chan1,2, Loh Teng-Hern Tan3,4, Kok-Gan Chan5, Learn-Han Lee6,7,8, Bey-Hing Goh9,10,11.
Abstract
Nerolidol (3,7,11-trimethyl-1,6,10-dodecatrien-3-ol) is a naturally occurring sesquiterpene alcohol that is present in various plants with a floral odor. It is synthesized as an intermediate in the production of (3E)-4,8-dimethy-1,3,7-nonatriene (DMNT), a herbivore-induced volatile that protects plants from herbivore damage. Chemically, nerolidol exists in two geometric isomers, a trans and a cis form. The usage of nerolidol is widespread across different industries. It has been widely used in cosmetics (e.g., shampoos and perfumes) and in non-cosmetic products (e.g., detergents and cleansers). In fact, U.S. Food and Drug Administration (FDA) has also permitted the use of nerolidol as a food flavoring agent. The fact that nerolidol is a common ingredient in many products has attracted researchers to explore more medicinal properties of nerolidol that may exert beneficial effect on human health. Therefore, the aim of this review is to compile and consolidate the data on the various pharmacological and biological activities displayed by nerolidol. Furthermore, this review also includes pharmacokinetic and toxicological studies of nerolidol. In summary, the various pharmacological and biological activities demonstrated in this review highlight the prospects of nerolidol as a promising chemical or drug candidate in the field of agriculture and medicine.Entities:
Keywords: cis-nerolidol; essential oil; pharmacological activities; sesquiterpene; trans-nerolidol
Mesh:
Substances:
Year: 2016 PMID: 27136520 PMCID: PMC6272852 DOI: 10.3390/molecules21050529
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures of the two enantiomers both for cis- and trans-isomers of nerolidol.
Synonyms of cis- and trans-nerolidol.
| (i) (±)- | (i) (±)- |
| (ii) (6 | (ii) (6 |
| (iii) (6 | (iii) (6 |
| (iv) (6 | (iv) (6 |
| (v) 1,6,10-dodecatrien-3-ol, 3,7,11-trimethyl-, (6 | (v) 1,6,10-dodecatrien-3-ol, 3,7,11-trimethyl-, (6 |
| (vi) ( | (vi) ( |
Plant sources of nerolidol along with its percentage of nerolidol and extraction method.
| Plant Part | Type of Nerolidol Found in the Essential Oil | Nerolidol Purified from the Essential Oil of the Respective Plants (%) | Extraction Method | Ref. |
|---|---|---|---|---|
| Aerial parts | (i) | Hydrodistillation technique using the Clevenger-type apparatus | [ | |
| (ii) | ||||
| (iii) | ||||
| (iv) | ||||
| Leaf | Nerolidol (n.s.) | (i) | Hydrodistillation technique using the Clevenger-type apparatus | [ |
| (ii) | ||||
| Molecular distillation at a feed temperature of 60 °C, distillation temperature of 280 °C, feed flow rate of 180 mL per hour, scraper rate of 300 rpm, and operating pressure of 0.1–0.5 Pa | [ | |||
| (i) | Hydrodistillation technique using the Clevenger-type apparatus | [ | ||
| (ii) | ||||
| (iii) | ||||
| (iv) | ||||
| (v) | ||||
| (vi) | ||||
| (vii) | ||||
| (viii) | ||||
| (ix) | ||||
| (x) | ||||
| (xi) | ||||
| (xii) | ||||
| (xiii) | ||||
| (xiv) | ||||
| Stem | Steam distillation using a low pressure system with an external steam source | [ | ||
| Flower | (i) | Hydrodistillation technique using the Clevenger-type apparatus | [ | |
| (ii) | ||||
| (iii) | ||||
| Root | Steam distillation using a low pressure system with an external steam source | [ | ||
| Seed/grain | Nerolidol (n.s.) | Hydrodistillation technique using the Clevenger-type apparatus | [ | |
| (i) | Hydrodistillation technique using the Clevenger-type apparatus | [ | ||
| (ii) | ||||
| Fruit | Hydrodistillation technique using the Clevenger-type apparatus | [ | ||
| Resin | Hydrodistillation technique using the Clevenger-type apparatus | [ | ||
| Twig/wood | Hydrodistillation technique using the Clevenger-type apparatus | [ | ||
| Solid-phase microextraction | [ | |||
| Hydrodistillation technique using the Clevenger-type apparatus | [ |
Key: n.s. = not specified.
Retention indices of different chromatographic columns of GC and major peaks of mass spectrometry to differentiate cis- and trans-nerolidol.
| Types of Column/Equipment Used | Ref. | ||
|---|---|---|---|
| (i) A-100 or 154-C column | 14 | 16 | [ |
| (ii) DB-5 capillary column | n.a. | 10.5 | [ |
| (iii) TR-5MS capillary column | 5.87 | 5.98 | [ |
| (i) Hypersil BDS C18 column | 11.9 | 13.1 | [ |
| (i) M-80B gas chromatograph double focusing mass spectrometer | 41, 69, 134, 91, 93, 79 | 69, 41, 93, 43, 71, 55 | [ |
| (ii) Y2K ion trap (MS) PolarisQ System mass spectrometer | 93, 91, 67, 107, 79, 161, 121, 133, 55, 147, 189, 175 | 93, 121, 67, 107, 79, 161, 136, 55, 189, 148, 175 | [ |
| (i) HP-101 | n.a. | 1564 | [ |
| (ii) HP-20M | n.a. | 2009 | [ |
| (iii) HP-FFAP | n.a. | 2055 | [ |
| (iv) Fused silica capillary column coated with DB-5 | n.a. | 1564 | [ |
| (v) OV-101 | 1533 | 1549 | [ |
| (vi) PEG 20M | 2028 | 2035 | [ |
| (vii) DB-5 | 1565 | 1539 | [ |
| (viii) DB-Wax | 2010 | 2054 | [ |
| (ix) SPB-1 | 1543 | n.a. | [ |
| (x) Dimethylsilicone (DIMS) | 1524.4 (a) | 1550.1 (a) | [ |
| (xi) Dimethylsilicone with 5% phenyl groups (DIMS5P) | 1543.6 (a) | 1560.9 (a) | [ |
| (xii) Polyethylene glycol (PEG) | 2007.3 (a) | 2036.3 (a) | [ |
Key: (a) = average value; n.a. = not available.
Scheme 1The overall chemical synthesis pathway of nerolidol to fulfill the demand of nerolidol in the industrial sector.
Scheme 2The biosynthesis pathway of (3S)-(E)-nerolidol as an intermediate product for the production of DMNT as an herbivore-induced volatile to protect the plant against herbivore damage.
A summary of pharmacological and biological activities of nerolidol.
| Bioactivity | Type of Nerolidol | Plant and Part of Plant Used (If Any) | Target Organism(s) | Screening Assay and Methods Used | Results | Possible Mechanisms of Action | Ref. |
|---|---|---|---|---|---|---|---|
| Antioxidant activity | - | - | DPPH and hydroxyl radical scavenging activity | (i) Exhibited DPPH radical scavenging activity | Mediates antioxidant activities via free radical scavenging activity | [ | |
| (ii) Exhibited scavenging activity against hydroxyl radical with IC50 = 1.48 mM | |||||||
| - | - | Thiobarbituric acid reactive substances (TBARS) assay | (i) Demonstrated 25.60% ± 0.98% malonaldehyde (MDA) reduction in hepatocytes at 1 mM under physiological conditions | Mediates antioxidant activity via lipid peroxidation inhibitory effect | [ | ||
| (ii) Demonstrated higher MDA reduction with value of 36.50% ± 4.47% at 1 mM in hepatocytes under oxidative stress induced by | |||||||
| Mixture of | - | - | TBARS assay, nitrite assay, superoxide dismutase (SOD) activity and catalase activity | (i) At doses of 25, 50 and 75 mg/kg of nerolidol caused a significant decrease in lipid peroxidation by 59.97%, 74.79% and 91.31% respectively when compared to negative control | (i) Suggested to prevent oxidation of polyunsaturated fatty acids | ||
| (ii) At doses of 25, 50 and 75 mg/kg of nerolidol caused a significant decrease in nitrite level by 71.1%, 66.6% and 63.35 % respectively when compared to negative control | |||||||
| (iii) At doses of 25, 50 and 75 mg/kg of nerolidol increased superoxide dismutase activity by 31.1%, 34.8% and 66.1%, respectively when compared to negative control | (ii) Suggested to inactivate the enzyme nitric oxide synthase | [ | |||||
| (iv) At doses of 25, 50 and 75 mg/kg of nerolidol increased catalase enzymatic activity by 109%, 148% and 177.7%, respectively when compared to negative control | |||||||
| Antibacterial activity | Mixture of | - | Broth-dilution with shaking method (BDS) | Exhibited dose-related inhibition against 34 clinical isolates of | Suggested the aliphatic chain of nerolidol mediates the antibacterial activity by damaging the bacterial cell membrane | [ | |
| Mixture of | - | Broth dilution with shaking (BDS) method and quantitation of the leakage of K+ ions using K+-selective electrode | Treatment of nerolidol caused a dose-dependent increase in amount of K+ ions leakage from bacterial cells. | Mediates the antibacterial activity via cell membrane-distrupting mechanism and hence resulting in the leakage of K+ ions from bacterial cells | [ | ||
| Mixture of | - | Broth dilution with shaking (BDS) method and quantitation of the leakage of K+ ions using K+-selective electrode | (i) Caused a dose-dependent increase in K+ ions leakage from bacterial cells | [ | |||
| (ii) Exhibited minimum inhibitory concentration at 40 μg/mL | |||||||
| Broth microdilution method (MIC) | (i) Exhibited anti-microbial activity with MIC ranged from 125–500 μg/mL. | - | [ | ||||
| Nerolidol (n.s.) | Broth dilution method | Exhibited antibacterial activity against | - | [ | |||
| Nerolidol (n.s.) | Disc-diffusion and broth dilution methods | (i) Exhibited antibacterial activity against | - | [ | |||
| - | Agar-disc diffusion assay | Nerolidol ( | - | [ | |||
| (i) amoxicillin/clavulanic acid against | |||||||
| (ii) amoxicilline/clavulanic acid, ceftadizine and imipenem against | |||||||
| Nerolidol (n.s.) (Sigma, St. Louis, MO, USA) | Disc-diffusion assay | (i) Nerolidol concentrations ranged from 0.5 to 2 mM enhanced the susceptibility of | - | [ | |||
| (ii) Nerolidol (1 mM) enhanced the susceptibility of | |||||||
| Racemic mixture of | - | Antibiotic disc assay | Nerolidol (20 mM) potentiated the susceptibility of | - | [ | ||
| Anti-biofilm activity | Mixture of | Black pepper, cananga, and myrrh EOs (Berjé (Bloomfield, NJ, USA), Jin Aromatics (Anyang, Gyeonggi Province, Korea) and Sigma-Aldrich (St. Louis, USA)) | Crystal violet biofilm assay | - | [ | ||
| MTT assay | Concentrations of 0.06%–1.0% inhibited biofilm formation by 30% and 50% after 24 and 48 h incubation respectively | - | [ | ||||
| - | MTT assay | 1.0% of | - | [ | |||
| Anti-fungal activity | Nerolidol (n.s.) | Broth microdilution method Skin lesion scoring in guinea pig model | (i) Exhibited MIC concentrations of 0.5%–2% against | - | [ | ||
| (ii) Nerolidol-treated group exhibited a significant improvement ( | |||||||
| Broth microdilution and trypan blue exclusion method | (i) Exhibited anti-fungal activity with MIC values ranging from 0.24% to 1.26%. | - | [ | ||||
| (ii) Exhibited inhibitory effect on yeast-to-hyphae transition by 81% | |||||||
| Nerolidol (n.s.) (Sigma-Aldrich, Yongin, Korea) | - | Agar dilution method | Inhibited the hyphal growth of | - | [ | ||
| Nerolidol (n.s.) | Broth dilution method | Inhibited the growth of | - | [ | |||
| Poison food (PF) technique | (i) | - | [ | ||||
| (ii) | |||||||
| Spore germination assay and agar dilution method | Caused 55.1%–70.3% growth inhibition at concentration ranging from 125 to 500 µg/mL. | - | [ | ||||
| Poisoned food (PF) technique and volatile activity (VA) assay | Inhibited the fungal spore production of | - | [ | ||||
| Nerolidol | Disc diffusion method; scanning electron microscopy | (i) Nerolidol ranged from 2.0 to 5.0 µg/disc displayed fungistatic property by inhibiting mycelial growth by ~85% | - | [ | |||
| (ii) Nerolidol ranged from 2.0 to 5.0 µg/disc inhibited the production of sclerotial by ~84% | |||||||
| (ii) Nerolidol at 4.0 µg/disc caused morphological alterations such as shorter branching, hyphal shrinkage and partial distortion | |||||||
| Anti-trypanosomal activity | Alamar Blue™ assay. | Exhibited anti-trypanosomal activity with IC50 measured at 1.7 µg/mL (7.6 µM) | - | [ | |||
| Trypanocidal and cytotoxic assays | Exhibited anti-trypanosomal activity with IC50 measured at 15.78 µg/mL | - | [ | ||||
| Mixture of ±40% | - | Collection of blood samples from | (i) Adverse morphological changes observed in nerolidol-treated group. The parasites lost their undulating membrane after 23 day post-treatment. | - | [ | ||
| (ii) Total disfigurement observed after 27 day post-treatment | |||||||
| Anti-leishmanial activity | A mixture of | - | MTT assay and metabolic labeling with [2-14C] mevalonic acid, [1-14C] acetic acid, [1(n)-3H] farnesyl pyrophosphate and | (i) Inhibited the growth of | Inhibition of the isoprenoid biosynthesis pathway | [ | |
| (ii) Nerolidol at 100 µM reduced the percentage of intracellular parasitism of | |||||||
| Parasite lactate dehydrogenase (pLDH) assay, antileishmanial assay, schistosomicidal assay and cytotoxicity assay using the mammalian cells | Exhibited anti-leishmanial activity against promastigotes of | - | [ | ||||
| Nerolidol | Protozoal arginase activity, nitrite determination and cytotoxicity assay using L929 fibroblast cells (mouse) and Raw cells (mouse macrophages) | (i) Nerolidol inhibited the arginase activity by 62.17% in the promastigotes of | Interferes with parasite-host cell interaction | [ | |||
| (ii) Nerolidol caused an increase in NO production (20.5%) | |||||||
| Nerolidol (n.s.) (Acros Organics, Geel, Belgium) | - | Promastigotes of | Anti-proliferative activity assay and electron paramagnetic resonance (EPR) spectroscopy of the spin-labeled 5-doxyl stearic acid | Nerolidol modulated the molecular dynamics of the lipid component in the | Insertion of nerolidol into the lipid bilayer increased the fluidity of membranes, thus causing leakage of cytoplasmic content and eventually the death of | [ | |
| Anti-schistosomal activity | Nerolidol (n.s.) | Schistosomicidal assay | 100% mortality of | - | [ | ||
| Racemic mixture of | - | Exhibited anti-schistosomal activity by reducing worm motor activity and caused 100% mortality of male and female schistosomes at concentration of 31.2 and 62.5 µM respectively | (i) Induced severe tegumental damage in adult schistosomes. | [ | |||
| (ii) Caused alterations on the tubercles of male parasites | |||||||
| Anti-malarial activity | Nerolidol (n.s.) | Treatment with 100 µg/mL of nerolidol caused 100% inhibition in the development of young trophozoite to the schizont stage after 48 h | - | [ | |||
| Exerted anti-malarial activity with IC50 of 11.1 μg/mL | - | [ | |||||
| Nerolidol (n.s.) (Sigma, St. Louis, MO, USA) | - | Immunoprecipitation assays and metabolic labeling | Exhibited inhibitory activity on the biosynthesis of the isoprenic side chain of the benzoquinone ring in ubiquinones during the schizont stage | Interferes with the elongation of isoprenic chains via inhibition of isoprenyl diphosphate synthases | [ | ||
| Nerolidol (n.s.) (Sigma, St. Louis, MO, USA) | - | Nerolidol at 50 nM inhibited the synthesis of the isoprenic chain attached to coenzyme Q at all intraerythrocytic stages | - | [ | |||
| Nerolidol (n.s.) | - | Isobolographic analysis | Nerolidol mediated supra-additive (the sum of the fractions of IC50 of < 1) interaction with fosmidomycin and squalestatin with average IC50 values of 0.57 and 0.62 µM, respectively in the inhibition of plasmodial isoprenoid pathway | - | [ | ||
| Other anti-parasite activities | Mixture of | - | Four | Inhibited | Inhibits the isoprenoid biosynthesis pathway in a similar mechanism with that of | [ | |
| Mixture of | - | Mortality assay against | Caused 74.0% mortality of | - | [ | ||
| Nerolidol (n.s.) | - | L3 larvae of | (i) Nerolidol at both 31.5 and 62.5 µg/mL resulted in 100% mortality of L3 larvae of | - | [ | ||
| (ii) Only 20% of nerolidol-treated rats were affected by gastric wall lesions caused by | |||||||
| Insecticidal activity | Siam-wood ( | Mosquito and house flies | House fly toxicity test | Exhibited insecticidal activity with LD50 measured at 0.17 µmol/fly | - | [ | |
| Combination of nerolidol (n.s.) and linalool | Maize weevil ( | Repellency assay using a glass Y-tube Olfactometer | Exhibited mean repellency value of 58.23% ± 2.95% against | - | [ | ||
| Nerolidol (n.s.) (Moellhausen SpA,Vimercate, Milano, Italy) | Pediculicidal and ovicidal activities | Nerolidol in combination with tea tree oil with ratio of 1:2 (tea tree oil 0.5% plus nerolidol 1%), exerted a total killing effect of lice within 30 min and abortive effect of louse eggs after 5 days. | - | [ | |||
| Nerolidol (n.s.) | Direct-contact mortality bioassay | Exerted larvacidal activity against | - | [ | |||
| Larvicidal activity test | Exerted larvicidal activity with ≥ 95% and > 80% mortality of | - | [ | ||||
| Fumigant, contact, repellency and two-choice assay | Exerted acaricidal activity with repellency value of 83.2% ± 0.59 % at 9.8 µg/mL | - | [ | ||||
| Nerolidol (n.s.) | Larval packet test (LPT) and engorged female immersion test | (i) Exerted acaricidal activity when concentration more than 5mg/mL and 100% mortality of larvae at 15 mg/mL | - | [ | |||
| (ii) Reduced the quality of the egg and larval hatching rate with increasing concentration from 20 to 50 mg/mL | |||||||
| Antiulcer activity | Nerolidol (n.s.) | - | Nerolidol displayed gastroprotective activity by inhibiting the formation of ulcers induced by all physical and chemical agents in dose-dependent manner (50, 250, 500 mg/kg) | - | [ | ||
| Skin penetration enhancer activity | Nerolidol (n.s.) (Aldrich, Gillingham, UK) | - | - | Increased diffusion rate by over 20-fold for transdermal delivery of drugs such as 5-fluorouracil | Nerolidol exhibits a chemical structure that allows it to align within the lipid lamellae of the stratum corneum in order to disrupt the organization of stratum corneum | [ | |
| Nerolidol (n.s.) (Alfa Aesar Ltd., Haverhill, MA, USA) | - | - | Solubility studies, | The enhancement effect is increased with the increasing lipophilicity; the rank of order (nerolidol > farnesol > limonene > linalool > geraniol > carvone > fenchone > menthol) in facilitating transdermal delivery of alfuzosin hydrochloride | [ | ||
| Nerolidol (n.s.) (Merck-Schuchardt, Hohenbrunn, Germany) | - | - | Exhibited the highest permeation enhancing ability with a 3.2-fold increase in permeation of selegiline hydrochloride across the rat skin, followed by the effect of carvone (2.8-fold increase) and anethole (2.6-fold increase) | - | [ | ||
| Nerolidol (n.s.) (Aldrich Chemical Co. Milwaukee, WI, USA) | - | - | Most effective terpene enhancer for percutaneous permeation of four different drug models (nicardipine hydrochloride, hydrocortisone, carbamazepine, and tamoxifen) when compared to fenchone, thymol and limonene | - | [ | ||
| Anti-nociceptive and anti-inflammatory activities | - | (i) Chemical (acetic acid and formalin) and thermal (hot plate) models of nociception | - | [ | |||
| (ii) Carrageenan- and dextran-induced paw edema tests in rats croton oil-induced ear edema | |||||||
| (iii) Cell migration, rolling and adhesion activities | |||||||
| - | (i) Nociception induced by formalin | - | [ | ||||
| (ii) Evaluation of locomotor activity | |||||||
| (iii) Induction of acute gastric lesions | |||||||
| Nerolidol (n.s.) (Sigma, St. Louis, MO, USA) | - | - | (i) Rotarod, acetic acid-induced writhing, formalin and hot-plate tests | (i) For acetic acid-induced writhing test, at the doses of 200, 300 and 400 mg/kg, nerolidol reduced the frequency of acetic acid-induced writhing at all three doses tested compared to the mice in the control group (55% ± 1.1%, 53% ± 4.5%, and 41% ± 2.4%, respectively) | (i) Anti-nociceptive activtity of nerolidol was indicated to be mediated by GABAA receptors, as the use of bicuculline, a GABAA antagonist inhibited the effect of nerolidol in reducing the paw licking times | [ | |
| Anti-cancer or anti-tumor activity | Nerolidol (a combination of | - | - | Cytotoxicity assay on HeLa cell lines using CytoTox-96®-assay | Exhibited anticancer effect against HeLa cells with CC50 value at 1.5 ± 0.7 µM | - | [ |
| - | - | Cytotoxicity and cytoproliferative activity on HeLa cell lines using Cytotoxicity Detection Kit (LDH) and the Cell Proliferation Reagent WST-1, respectively | Exhibited cytotoxic effect (16.5 ± 6.7 μM) against HeLa cells | - | [ | ||
| Nerolidol (n.s.) | - | MTT assay | Exhibited cytotoxic effect with IC50 value of 2.96 and 3.02 µg/mL against BT-20 breast carcinoma and HeLa cells respectively | - | [ | ||
| - | (i) | - | [ | ||||
| (ii) The EO at dose of 100 mg/kg containing | |||||||
| - | Neutral red uptake (NRU) test, MTT assay and 2′,7′-dichlorodihydrofluorescein-diacetate (H2DCF-DA) oxidation | Potentiated the action of doxorubicin, an anticancer drug in the modulation of CaCo-2 cancer cells | - | [ | |||
| Nerolidol (n.s.) (Sigma Aldrich Chemical Company) | - | - | (i) Reduction of incidence of intestinal neoplasia from 82% to 33% in rats fed with nerolidol | Modulation of nerolidol on protein prenylation which responsible for the formation of cancer | [ | ||
| (ii) Reduction of number of tumors/rat from 1.5 to 0.7 in rats fed with nerolidol | |||||||
| Combination of farnesol and nerolidol (n.s.) | - | - | The combination suppressed the proliferation of human HL-60 acute promyelocytic leukemia (HL-60) cells by 20%. Meanwhile, farnesol isomers (2.5 µmol/L) and nerolidol (5 µmol/L) individually suppressed the proliferation of HL-60 cells by 4 and 9%, respectively | Nerolidol induced cell cycle arrest at the G0-G1/S interphase in HL-60 cells and eventually lead to apoptotic cell death | [ | ||
| - | Cell adhesion and apoptosis luminescent assays | (i) Reduced adhesion of HT29 to collagen. | Nerolidol induced apoptosis in cancer cells | [ | |||
| (ii) Suppressed cell adhesion of HT29 cells in the presence TNFα cytokines | |||||||
| (iii) Decreasing the phosphorylation of NF-κB and increased the activity of caspases |
Key: n.s. = not specified.
Figure 2The source of extraction of nerolidol and an overview of the biological activities of nerolidol.
Comparison of pharmacokinetic studies of nerolidol conducted by Saito et al. and He et al. [22,25]
| Parameters | Saito | He |
|---|---|---|
| Type of nerolidol | Mixture of | Mixture of |
| Analytical method used | GC-MS | LC-MS |
| Animal used | BALB/c mice | Sprague-Dawley rats |
| Route of administration | Oral | Intraperitoneal injection |
| Dosage (mg/kg) | 1000 | 25 |
| Type of sample used | Plasma | |
| Time collection taken (min) | 30, 60, 120, 180, 240, 300, 360, 480 and 720 | 10, 20, 30, 60, 90, 120, 240 and 360 |
| Peak plasma concentration (Cmax) (µg/mL) | ~0.27 ± 0.07 | 8.30 ± 1.07 |
| Peak time (Tmax) (min) | 30 | 20 |
| Elimination half life (T1/2) (min) | n.a. | 20.98 ± 7.71 |
| Mean residence time (MRT) (min) | n.a. | 27.72 ± 2.14 |
| Clearance (L/min/kg) | n.a. | 0.082 ± 0.012 |
| Time for drug to be eliminated to almost near zero | 12 | ~2 |
| Human equivalent dose a (HED) (mg/kg) | 81.08 | 4.05 |
Key: (i) n.a. = data not available; (ii) a = HED values were calculated based on the formula for dose translation based on body surface area (BSA) [156] as follows: Human equivalent dose (HED) (mg/kg) = Animal dose (mg/kg) × with adult human, rat and mouse Km factors of 37, 6 and 3 respectively [156].